Standard Lipid Panel

Total cholesterol represents the sum of cholesterol carried across all lipoprotein fractions, including LDL, HDL, and VLDL. Cholesterol is a sterol essential for cell membranes, steroid hormone synthesis, and bile acid production, derived from hepatic synthesis and dietary intake. Because it aggregates pro-atherogenic and protective fractions, total cholesterol is a coarse measure whose clinical meaning depends on its distribution among lipoproteins.

Total cholesterol is a long-standing component of cardiovascular risk assessment and screening, but its interpretation requires the accompanying HDL, LDL, and triglyceride values because a raised total can reflect either harmful LDL or protective HDL. It is most useful as part of the full panel and in risk-scoring algorithms rather than in isolation.

Low-density lipoprotein cholesterol is the principal atherogenic lipoprotein, delivering cholesterol to peripheral tissues and depositing it in the arterial wall during atherogenesis. In standard panels LDL-C is usually calculated (Friedewald or newer equations) rather than measured directly, which introduces error at high triglyceride levels and very low LDL-C. It is the primary target of lipid-lowering therapy.

LDL-C is the central treatment target in cardiovascular prevention, with progressively lower goals as risk increases. Lowering LDL-C reduces atherosclerotic cardiovascular events. Because it is typically calculated, LDL-C can be unreliable when triglycerides are high (above roughly 400 mg/dL) or LDL-C is very low, in which case a directly measured LDL-C or ApoB is preferred.

High-density lipoprotein cholesterol reflects cholesterol carried by HDL particles, which mediate reverse cholesterol transport from peripheral tissues to the liver. HDL-C has traditionally been regarded as protective, with an inverse epidemiological association with cardiovascular risk. However, very high HDL-C does not confer additional benefit and HDL-raising interventions have not reliably reduced events, so HDL-C is best treated as a risk marker rather than a therapeutic target.

HDL-C is used in risk assessment and risk-scoring algorithms, where a low level marks increased cardiovascular risk. It contextualises total cholesterol and contributes to the total-cholesterol-to-HDL ratio and non-HDL calculation. It is interpreted as a risk marker rather than a treatment goal.

Triglycerides are the principal storage lipids, transported in chylomicrons and VLDL. Serum triglycerides rise after meals, which is why fasting samples are traditionally used, and are influenced strongly by carbohydrate and alcohol intake, adiposity, and insulin resistance. Very high triglycerides carry a risk of pancreatitis independent of atherosclerotic risk.

Triglycerides contribute to cardiovascular risk assessment and are a marker of metabolic dysfunction and insulin resistance. They are required for the Friedewald calculation of LDL-C, which becomes unreliable at high triglyceride levels. Markedly elevated triglycerides (above ~500 mg/dL) raise the risk of acute pancreatitis and warrant specific management.

Non-HDL cholesterol is calculated as total cholesterol minus HDL-C and captures the cholesterol carried by all atherogenic, apolipoprotein-B-containing particles, including LDL, VLDL, and remnants. Because it does not rely on the triglyceride-dependent Friedewald calculation, it remains reliable in non-fasting samples and at higher triglyceride levels.

Non-HDL-C is an increasingly favoured risk marker and secondary treatment target, particularly in patients with high triglycerides, diabetes, or metabolic syndrome, where calculated LDL-C underestimates atherogenic burden. It correlates closely with ApoB and can be derived from the standard panel without additional testing.